Gall Matthew 4

What Happened
Matthew Gall, Chief Financial Officer of Tango Therapeutics (TNGX), received equity awards reported on Form 4 dated May 5, 2026 for transactions on May 1, 2026. The awards consist of 40,000 restricted stock units (RSUs) and a derivative grant covering 240,000 shares (an option). Both were recorded at $0.00 acquisition price in the filing (typical for RSU and option grants); the reported economic value at grant (exercise price for the option) is not shown in the provided data.

Key Details

• Transaction date: 2026-05-01; Form 4 filed: 2026-05-05 (filed within the SEC’s two-business-day window).
• Reported acquisitions: 40,000 RSUs (ordinary shares-equivalent) and a 240,000-share option (derivative). Price reported: $0.00 for both (award/option grant).
• Shares owned after the transaction: not specified in the provided excerpt.
• Footnote F1 (RSUs): RSUs convert to one common share each and vest over three years — 13,200 RSUs ~May 10, 2027; 13,200 ~May 10, 2028; 13,600 ~May 9, 2029 — subject to continuous service.
• Footnote F2 (option): Option vests over four years — 25% on April 15, 2027, then remaining shares vest in 36 equal monthly installments — subject to continuous service.
• No indication in the filing that any shares were immediately sold, that this is a gift, or that a 10b5-1 plan was used.

Context
These are compensation awards (an RSU grant and an option grant), not open-market purchases or sales. RSUs convert to actual shares only as they vest; options give the right to buy shares later (vesting schedule applies), so these grants are forward-looking and conditional on continued service. Such awards are common executive compensation and do not, by themselves, indicate an immediate change in insider sentiment about the stock.